Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BNT324 + BNT327 in advanced lung cancer
CTR20252732Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of db-1311, pumitamig in bronchial carcinoma, sponsored by AbbVie Inc.. Started Sep 2025; status: active.
02
Drugs
db-1311pumitamig
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on CTR20252732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252732.